<DOC>
	<DOCNO>NCT00346684</DOCNO>
	<brief_summary>First line therapy patient Lymphocyte predominant Hodgkin´s Disease ( LPHD ) clinical stage IA use monoclonal anti-CD20 antibody rituximab</brief_summary>
	<brief_title>Rituximab Primary Lymphocyte Predominant Hodgkin´s Disease ( RIPL )</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>lymphocyte predominant Hodgkin´s lymphoma ( histologically proven ) clinical stage IA ( without risk factor : large mediastinal mass , extranodal involvement , ESR &gt; 50mm/h ) age 18 75 WHO performance status 03 normal organ function write informed consent classical Hodgkin´s lymphoma composite lymphoma leucocytes &lt; 3000/µl thrombocyte &lt; 100.000/µl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>LPHD</keyword>
	<keyword>Rituximab</keyword>
</DOC>